Neuromuscular complications of immune checkpoint inhibitors - 09/11/18
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
This article has been published in an issue click here to access
Highlights |
• | Neurological irAE are very uncommon in cancer patients with ICIs treatment, in less than 3% of the patients, but with potentially poor outcome. |
• | ICI-associated myositis with or without myasthenia gravis are the more frequent complications and respond well to corticosteroid therapy and ICIs discontinuation. |
• | Oculobulbar involvement is unique and common among patients with ICI-associated myositis. |
• | Myocarditis is occasionally associated in irMyositis and consists with diaphragm disorder pejoratives prognostic factors. |
Summary |
Immune checkpoint inhibitors have been increasingly used in patients with various cancers. Despite favourable oncological outcomes these treatments have also been associated with immune-related adverse events. Neurological irAE are rare but potentially severe and neuromuscular complications are the most common. This is a new group of neurologic complications of systemic anticancer therapies, often responsive to immune-modulating therapies. Early recognition and treatment are crucial for timely improvement of functional outcome and requires a multidisciplinary approach.
El texto completo de este artículo está disponible en PDF.Esquema
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.